Literature DB >> 20447541

Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism.

Claudia Dellas1, Miriam Puls, Mareike Lankeit, Katrin Schäfer, Mayumi Cuny, Maik Berner, Gerd Hasenfuss, Stavros Konstantinides.   

Abstract

OBJECTIVES: We assessed the predictive value of heart-type fatty acid-binding protein (H-FABP) in normotensive patients with acute pulmonary embolism (PE).
BACKGROUND: Risk stratification of initially normotensive patients with PE on the basis of right ventricular dysfunction or injury remains controversial. Previous studies investigating biomarkers or imaging modalities included unselected patients, some of whom presented with cardiogenic shock.
METHODS: We included 126 consecutive normotensive patients with confirmed PE. Complicated 30-day outcome was defined as death, resuscitation, intubation, or use of catecholamines. Long-term survival was assessed by follow-up clinical examination.
RESULTS: During the first 30 days, 9 (7%) patients suffered complications. These patients had higher baseline H-FABP values (median, 11.2 ng/ml [interquartile range: 8.0 to 36.8 ng/ml]) compared with patients with an uncomplicated course (3.4 ng/ml [2.1 to 4.9 ng/ml]; p < 0.001). H-FABP values were above the calculated (by receiver operating characteristic curve analysis) cutoff value of 6 ng/ml in 29 patients. Eight (28%) of them suffered complications versus 1 of 97 patients with low H-FABP (negative predictive value, 99%; p < 0.001). By logistic regression, elevated (> or =6 ng/ml) H-FABP was associated with a 36.6-fold increase in the death or complication risk. The combination of H-FABP with tachycardia was a particularly useful prognostic indicator. H-FABP also predicted long-term mortality over 499 (interquartile range: 204 to 1,166) days (hazard ratio: 3.6; 95% confidence interval: 1.6 to 8.2; p = 0.003).
CONCLUSIONS: The H-FABP might be a useful biomarker for risk stratification of normotensive patients with acute PE. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447541     DOI: 10.1016/j.jacc.2009.10.078

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  21 in total

1.  Management of submassive pulmonary embolism.

Authors:  Gregory Piazza; Samuel Z Goldhaber
Journal:  Circulation       Date:  2010-09-14       Impact factor: 29.690

2.  Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism.

Authors:  F A Klok; C Niemann; C Dellas; G Hasenfuß; S Konstantinides; M Lankeit
Journal:  J Thromb Thrombolysis       Date:  2016-02       Impact factor: 2.300

3.  Prognostic impact of the serum heart-type fatty acid-binding protein (H-FABP) levels in patients admitted to the non-surgical intensive care unit.

Authors:  Akihiro Shirakabe; Nobuaki Kobayashi; Noritake Hata; Masanori Yamamoto; Takuro Shinada; Kazunori Tomita; Masafumi Tsurumi; Masato Matsushita; Hirotake Okazaki; Yoshiya Yamamoto; Shinya Yokoyama; Kuniya Asai; Wataru Shimizu
Journal:  Clin Res Cardiol       Date:  2014-05-10       Impact factor: 5.460

4.  H-FABP, cardiovascular risk factors, and functional status in asymptomatic spinal cord injury patients.

Authors:  A Akbal; A Kurtaran; B Selçuk; M Akyüz
Journal:  Herz       Date:  2013-03-14       Impact factor: 1.443

5.  Heart-type fatty acid-binding protein: an overlooked cardiac biomarker.

Authors:  Harsh Goel; Joshua Melot; Matthew D Krinock; Ashish Kumar; Sunil K Nadar; Gregory Y H Lip
Journal:  Ann Med       Date:  2020-08-04       Impact factor: 4.709

6.  Thrombolysis in patients with pulmonary embolism and elevated heart-type fatty acid-binding protein levels.

Authors:  Enes Elvin Gul; Ilknur Can; Mehmet Kayrak; Turyan Abdulhalikov; Halil Ibrahim Erdogan; Gokhan Altunbas; Kurtulus Ozdemir; Hasan Gok
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

Review 7.  Risk stratification of patients with acute symptomatic pulmonary embolism.

Authors:  David Jiménez; Jose Luis Lobo; Deisy Barrios; Paolo Prandoni; Roger D Yusen
Journal:  Intern Emerg Med       Date:  2016-01-14       Impact factor: 3.397

8.  A simple score for rapid risk assessment of non-high-risk pulmonary embolism.

Authors:  Mareike Lankeit; Dietrich Friesen; Katrin Schäfer; Gerd Hasenfuß; Stavros Konstantinides; Claudia Dellas
Journal:  Clin Res Cardiol       Date:  2012-08-09       Impact factor: 5.460

9.  Joint analysis of D-dimer, N-terminal pro b-type natriuretic peptide, and cardiac troponin I on predicting acute pulmonary embolism relapse and mortality.

Authors:  Xiaoyu Liu; Liying Zheng; Jing Han; Lu Song; Hemei Geng; Yunqiu Liu
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

10.  Management of massive and nonmassive pulmonary embolism.

Authors:  Vishal Sekhri; Nimeshkumar Mehta; Naveen Rawat; Stuart G Lehrman; Wilbert S Aronow
Journal:  Arch Med Sci       Date:  2012-12-19       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.